World Journal of Cardiology最新文献

{"title":"Impact of single chamber and dual chamber permanent pacemaker implantation on left ventricular function: An observational study.","authors":"Merajul Haque, Monika Bhandari, Akshyaya Pradhan, Pravesh Vishwakarma, Abhishek Singh, Ayush Shukla, Akhil Sharma, Gaurav Chaudhary, Rishi Sethi, Sharad Chandra, Arvind Jaiswal, Sudhanshu Kumar Dwivedi","doi":"10.4330/wjc.v16.i11.644","DOIUrl":"10.4330/wjc.v16.i11.644","url":null,"abstract":"<p><strong>Background: </strong>Permanent pacemaker implantation has the potential to impact left ventricular (LV) function and hence quality of life (QoL) in the long term.</p><p><strong>Aim: </strong>To assess the effect of single- and dual-chamber pacing on LV function and QoL.</p><p><strong>Methods: </strong>This study included 56 patients who underwent permanent pacing: Dual pacing, dual sensing, dual responsive and rate responsive (DDDR) for the initial 3 months and ventricular pacing, ventricular sensing, inhibited response and rate responsive (VVIR) for the next 3 months, and DDDR mode for the last 3 months. Throughout the study period, various echocardiographic parameters, functional status, and QoL were measured to assess the impact of pacing on LV function compared with baseline and at every 3 months interval.</p><p><strong>Results: </strong>A significant change appeared in cardiac function after VVIR pacing which included diastolic properties of LV as shown by increase in isovolumic relaxation time from (85.28 ± 9.54 ms) to (89.53 ± 9.65 ms). At the 3-, 6-, and 9-month follow-up, reduction in LV ejection fraction was observed to be 62.71 ± 4.66%, 61.07 ± 4.41%, and 58.48 ± 3.89%, respectively. An increase in the QoL scores was noted at every follow-up visit.</p><p><strong>Conclusion: </strong>An apparent depressant effect on LV function due to right ventricular pacing, with a higher incidence of adverse outcomes in the VVIR mode. In addition, an upsurge in QoL scores for the study population was noted, which indicates improvement in the QoL of patients post-pacing, irrespective of the mode. Generally, the DDDR mode is a highly preferable pacing mode.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"16 11","pages":"644-650"},"PeriodicalIF":1.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142732659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Living biodrugs and how tissue source influences mesenchymal stem cell therapeutics for heart failure.","authors":"Siddharth Shah, Huzaifa Sabir Nawaz, Muhammad Saeed Qazi, Hritvik Jain, Brandon Lucke-Wold","doi":"10.4330/wjc.v16.i11.619","DOIUrl":"10.4330/wjc.v16.i11.619","url":null,"abstract":"<p><p>In this editorial we comment on the article by Safwan M <i>et al</i>. We especially focused on the cardiac function restoration by the use of mesenchymal stem cells (MSCs) therapy for heart failure (HF), which has emerged as a new treatment approach as \"Living Biodrugs\". HF remains a significant clinical challenge due to the heart's inability to pump blood effectively, despite advancements in medical and device-based therapies. MSCs have emerged as a promising therapeutic approach, offering benefits beyond traditional treatments through their ability to modulate inflammation, reduce fibrosis, and promote endogenous tissue regeneration. MSCs can be derived from various tissues, including bone marrow and umbilical cord. Umbilical cord-derived MSCs exhibit superior expansion capabilities, making them an attractive option for HF therapy. Conversely, bone marrow-derived MSCs have been extensively studied for their potential to improve cardiac function but face challenges related to cell retention and delivery. Future research is focusing on optimizing MSC sources, enhancing differentiation and immune modulation, and improving delivery methods to overcome current limitations.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"16 11","pages":"619-625"},"PeriodicalIF":1.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142732986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of sodium-dependent glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus and asymptomatic heart failure.","authors":"Mohamed H Laimoud, Ismail R Raslan","doi":"10.4330/wjc.v16.i11.665","DOIUrl":"10.4330/wjc.v16.i11.665","url":null,"abstract":"<p><p>Sodium-dependent glucose transporter 2 inhibitors (SGLT2i) have been increasingly used with proven efficacy in patients with heart failure (HF), regardless of diabetes status. Grubić Rotkvić <i>et al</i> recently published an observational study on SGLT2i therapy in patients with type 2 diabetes mellitus and asymptomatic HF. They found that the use of SGLT2i led to reduced cardiac load and improved cardiovascular performance, reinforcing the evolving paradigm that SGLT2i are not merely glucose-lowering agents but are integral to the broader management of cardiovascular risk in patients with type 2 diabetes mellitus. The study by Grubić Rotkvić <i>et al</i> contributes to the growing body of literature supporting the early use of SGLT2i in patients with diabetic cardiomyopathy, offering a potential strategy to mitigate the progression of HF. Future larger studies should be conducted to confirm these findings, and explore the long-term cardiovascular benefits of SGLT2i, particularly in asymptomatic patients at risk of developing HF.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"16 11","pages":"665-668"},"PeriodicalIF":1.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142732624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-chamber pacing confers better myocardial performance and improves clinical outcomes compared to single-chamber pacing.","authors":"Bishav Mohan, Akash Batta","doi":"10.4330/wjc.v16.i11.626","DOIUrl":"10.4330/wjc.v16.i11.626","url":null,"abstract":"<p><p>The deleterious effects of long term right ventricular pacing are increasingly being recognized today. Current clinical practice favors the implantation of dual-chamber permanent pacemaker which maintains atrioventricular synchrony and is associated with better quality of life. However, despite the popular belief and common sense surrounding the superiority of dual-chamber pacing over single chamber pacing, the same has never been conclusively verified in clinical trials. Some observational evidence however, does exists which supports the improved cardiac hemodynamics, lower the rate of atrial fibrillation, heart failure and stroke in dual-chamber pacing compared to single-chamber pacing. In the index study by Haque <i>et al</i>, right ventricular pacing, particularly in ventricular paced, ventricular sensed, inhibited response and rate responsive pacemaker adversely impacted the left ventricular functions over 9-months compared to dual pacing, dual sensing, dual responsive and rate responsive pacemaker. Although there are key limitations of this study, these findings does support a growing body of evidence reinstating the superiority of dual chamber pacing compared to single chamber pacing.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"16 11","pages":"626-631"},"PeriodicalIF":1.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142732396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular and nonalcoholic fatty liver disease: Sharing common ground through SIRT1 pathways.","authors":"Kenneth Maiese","doi":"10.4330/wjc.v16.i11.632","DOIUrl":"10.4330/wjc.v16.i11.632","url":null,"abstract":"<p><p>As a non-communicable disease, cardiovascular disorders have become the leading cause of death for men and women. Of additional concern is that cardiovascular disease is linked to chronic comorbidity disorders that include nonalcoholic fatty liver disease (NAFLD). NAFLD, also termed metabolic-dysfunction-associated steatotic liver disease, is the greatest cause of liver disease throughout the world, increasing in prevalence concurrently with diabetes mellitus (DM), and can progress to nonalcoholic steatohepatitis that leads to cirrhosis and liver fibrosis. Individuals with metabolic disorders, such as DM, are more than two times likely to experience cardiac disease, stroke, and liver disease that includes NAFLD when compared individuals without metabolic disorders. Interestingly, cardiovascular disorders and NAFLD share a common underlying cellular mechanism for disease pathology, namely the silent mating type information regulation 2 homolog 1 (SIRT1; <i>Saccharomyces cerevisiae</i>). SIRT1, a histone deacetylase, is linked to metabolic pathways through nicotinamide adenine dinucleotide and can offer cellular protection though multiple avenues, including trophic factors such as erythropoietin, stem cells, and AMP-activated protein kinase. Translating SIRT1 pathways into clinical care for cardiovascular and hepatic disease can offer significant hope for patients, but further insights into the complexity of SIRT1 pathways are necessary for effective treatment regimens.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"16 11","pages":"632-643"},"PeriodicalIF":1.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142732349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 inhibitors in the prevention of diabetic cardiomyopathy: Targeting the silent threat.","authors":"Panayotis K Vlachakis, Panagiotis Theofilis, Dimitris Tousoulis","doi":"10.4330/wjc.v16.i11.669","DOIUrl":"10.4330/wjc.v16.i11.669","url":null,"abstract":"<p><p>Heart failure (HF) is a major global health challenge, particularly among individuals with type 2 diabetes mellitus (T2DM), who are at significantly higher risk of developing HF. Diabetic cardiomyopathy, a unique form of heart disease, often progresses silently until advanced stages. Recent research has focused on sodium-dependent glucose transporter 2 inhibitors (SGLT2i), originally developed for hyperglycemia, which have shown potential in reducing cardiovascular risks, including HF hospitalizations, irrespective of diabetic status. In this editorial we comment on the article by Grubić Rotkvić <i>et al</i> published in the recent issue of the <i>World Journal of Cardiology.</i> The investigators examined the effects of SGLT2i on myocardial function in T2DM patients with asymptomatic HF, finding significant improvements in stroke volume index and reductions in systemic vascular resistance, suggesting enhanced cardiac output. Additionally, SGLT2i demonstrated anti-inflammatory and antioxidant effects, as well as blood pressure reduction, though the study's limitations-such as small sample size and observational design-necessitate larger randomized trials to confirm these findings. The study underscores the potential of early intervention with SGLT2i in preventing HF progression in T2DM patients.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"16 11","pages":"669-672"},"PeriodicalIF":1.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142732991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac hypertrophy in polycythemia vera: A case report and review of literature.","authors":"Bai-Sheng Ma, Shu-Hui Zhai, Wei-Wei Chen, Qi-Ni Zhao","doi":"10.4330/wjc.v16.i11.651","DOIUrl":"10.4330/wjc.v16.i11.651","url":null,"abstract":"<p><strong>Background: </strong>The combination of polycythemia vera (PV) with pathological cardiac hypertrophy is uncommon. In this study, we describe a case of PV accompanied by pathological cardiac hypertrophy. It is hypothesized that the pronounced cardiac hypertrophy in this patient has a strong connection with PV.</p><p><strong>Case summary: </strong>In 2021, a 34-year-old Chinese man experienced chest constriction, shortness of breath, and palpitations during vigorous activity. Each episode lasted several minutes and resolved spontaneously following cessation of vigorous activity. He occasionally experienced syncope and vertigo without a headache. He underwent cardiac magnetic resonance imaging and was diagnosed with \"hypertrophic cardiomyopathy (HCM)\". He was discharged after receiving symptomatic treatment, which resulted in an improvement. He presented to our department with chest constriction, shortness of breath, and respiratory distress for one month while climbing to the second floor in 2023. His blood pressure was 180/100 mmHg at the time of admittance, and he was receiving antihypertensive treatment. He had a history of PV for 2 years without treatment. Symptomatic treatment was implemented concurrently with the administration of hydroxyurea upon admission. Good blood pressure control was observed during the long-term follow-up, and echocardiography did not reveal any progression of myocardial hypertrophy.</p><p><strong>Conclusion: </strong>Clinicians managing PV patients should remain highly vigilant regarding the risks of thrombosis and cardiovascular complications, particularly in those with refractory hypertension.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"16 11","pages":"651-659"},"PeriodicalIF":1.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142733196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and mechanisms of sodium-dependent glucose transporter 2 inhibitors in type 2 diabetes and heart failure patients.","authors":"Yan-Xi Zhang, Hai-Sheng Hu, Bao-Qing Sun","doi":"10.4330/wjc.v16.i10.611","DOIUrl":"10.4330/wjc.v16.i10.611","url":null,"abstract":"<p><p>We comment on an article by Grubić Rotkvić <i>et al</i> published in the recent issue of the <i>World Journal of Cardiology</i>. We specifically focused on possible factors affecting the therapeutic effectiveness of sodium-dependent glucose transporter inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and their impact on comorbidities. SGLT2i inhibits SGLT2 in the proximal tubules of the kidneys, lowering blood glucose levels by inhibiting glucose reabsorption by the kidneys and causing excess glucose to be excreted in the urine. Previous studies have demonstrated a role of SGLT2i in cardiovascular function in patients with diabetes who take metformin but still have poor glycemic control. In addition, SGLT2i has been shown to be effective in anti-apoptosis, weight loss, and cardiovascular protection. Accordingly, it is feasible to treat patients with T2DM with cardiovascular or renal diseases using SGLT2i.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"16 10","pages":"611-615"},"PeriodicalIF":1.9,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes.","authors":"Simona Cernea, Danusia Onișor, Andrada Larisa Roiban, Theodora Benedek, Nora Rat","doi":"10.4330/wjc.v16.i10.580","DOIUrl":"10.4330/wjc.v16.i10.580","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD), particularly in the presence of liver fibrosis, increases the risk of cardiovascular morbidity and mortality, but the nature of the cardio-hepatic interaction in the context type 2 diabetes mellitus (T2DM) is not fully understood.</p><p><strong>Aim: </strong>To evaluate the changes in cardiac morphology and function in patients with T2DM and MASLD-associated liver fibrosis.</p><p><strong>Methods: </strong>T2DM patients with MASLD underwent a medical evaluation that included an assessment of lifestyle, anthropometric measurements, vital signs, an extensive laboratory panel, and a standard echocardiography. Liver fibrosis was evaluated using two scores [Fibrosis-4 (FIB4) and Non-alcoholic fatty liver disease-Fibrosis Score (NFS)], and subjects were classified as having advanced fibrosis, no fibrosis, or an indeterminate risk. The correlations between structural and functional cardiac parameters and markers of liver fibrosis were evaluated through bivariate and multiple regression analyses. Statistical significance was set at <i>P</i> < 0.05.</p><p><strong>Results: </strong>Data from 267 T2DM-MASLD subjects with complete assessment was analyzed. Patients with scores indicating advanced fibrosis exhibited higher interventricular septum and left ventricular (LV) posterior wall thickness, atrial diameters, LV end-systolic volume, LV mass index (LVMi), and epicardial adipose tissue thickness (EATT). Their mean ejection fraction (EF) was significantly lower (49.19% ± 5.62% <i>vs</i> 50.87% ± 5.14% <i>vs</i> 52.00% ± 3.25%; <i>P</i> = 0.003), and a smaller proportion had an EF ≥ 50% (49.40% <i>vs</i> 68.90% <i>vs</i> 84.21%; <i>P</i> = 0.0017). Their total and mid LV wall motion score indexes were higher (<i>P</i> < 0.05). Additionally, they had markers of diastolic dysfunction, with a higher E/e' ratio [9.64 ± 4.10 <i>vs</i> 8.44 (2.43-26.33) <i>vs</i> 7.35 ± 2.62; <i>P</i> = 0.026], and over 70% had lateral e' values < 10 cm/second, though without significant differences between groups. In multiple regression analyses, FIB4 correlated with left atrium diameter (LAD; <i>β</i> = 0.044; <i>P</i> < 0.05), and NFS with both LAD (<i>β</i> = 0.039; <i>P</i> < 0.05) and right atrium diameter (<i>β</i> = 0.041; <i>P</i> < 0.01), Moreover, LVMi correlated positively with age and EATT (<i>β</i> = 1.997; <i>P</i> = 0.0008), and negatively with serum sex-hormone binding protein (SHBP) concentrations (<i>β</i> = -0.280; <i>P</i> = 0.004). SHBP also correlated negatively with LAD (<i>β</i> = -0.036; <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>T2DM patients with markers of MASLD-related liver fibrosis exhibit lower EF and present indicators of diastolic dysfunction and cardiac hypertrophy. Additionally, LVMi and LAD correlated negatively with serum SHBP concentrations.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"16 10","pages":"580-594"},"PeriodicalIF":1.9,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi, and Vici.","authors":"Monika Bhandari, Akshyaya Pradhan, Pravesh Vishwakarma, Abhishek Singh, Rishi Sethi","doi":"10.4330/wjc.v16.i10.550","DOIUrl":"10.4330/wjc.v16.i10.550","url":null,"abstract":"<p><p>Heart failure (HF) is a chronic disease associated with high morbidity and mortality rates. Renin-angiotensin-aldosterone system blockers (including angiotensin receptor/neprilysin inhibitors), beta-blockers, and mineralocorticoid receptor blockers remain the mainstay of pharmacotherapy for HF with reduced ejection fraction (HFrEF). However, despite the use of guideline-directed medical therapy, the mortality from HFrEF remains high. HF with preserved ejection fraction (HFpEF) comprises approximately half of the total incident HF cases; however, unlike HFrEF, there are no proven therapies for this condition. Sodium glucose cotransporter-2 inhibitors (SGLT-2is) represent a new class of pharmacological agents approved for diabetes mellitus (DM) that inhibit SGLT-2 receptors in the kidney. A serendipitous finding from seminal trials of SGLT-2is in DM was the significant improvement in renal and cardiovascular (CV) outcomes. More importantly, the improvement in HF hospitalization (HHF) in the CV outcomes trials of SGLT-2is was striking. Multiple mechanisms have been proposed for the pleiotropic effects of SGLT-2is beyond their glycemic control. However, as patients with HF were not included in any of these trials, it can be considered as a primary intervention. Subsequently, two landmark studies of SGLT-2is in patients with HFrEF, namely, an empagliflozin outcome trial in patients with chronic HF and a reduced ejection fraction (EMPEROR-Reduced) and dapagliflozin and prevention of adverse outcomes in HF (DAPA-HF), demonstrated significant improvement in HHF and CV mortality regardless of the presence of DM. These impressive results pitchforked these drugs as class I indications in patients with HFrEF across major guidelines. Thereafter, empagliflozin outcome trial in patients with chronic HF with preserved ejection fraction (EMPEROR-Preserved) and dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction HF (DELIVER) trials successively confirmed that SGLT-2is also benefit patients with HFpEF with or without DM. These results represent a watershed as they constitute the first clinically meaningful therapy for HFpEF in the past three decades of evolution of HF management. Emerging positive data for the use of SGLT-2is in acute HF and post-myocardial infarction scenarios have strengthened the pivotal role of these agents in the realm of HF. In a short span of time, these classes of drugs have captivated the entire scenario of HF.</p>","PeriodicalId":23800,"journal":{"name":"World Journal of Cardiology","volume":"16 10","pages":"550-563"},"PeriodicalIF":1.9,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11525799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}